Clinuvel Pharmaceuticals Limited
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsClinuvel Pharmaceuticals is an Australian specialty pharmaceutical company listed on the ASX with a secondary Nasdaq ADS listing, reporting $64.3M in fiscal 2026 revenue and $23.2M net income.
What they do
Clinuvel develops and commercializes prescription therapies, with its ordinary shares primarily listed on the ASX under 'CUV' and American Depositary Shares trading on Nasdaq under 'CUVL'. Each ADS represents one ordinary share, and The Bank of New York Mellon acts as depositary. The company is incorporated in Australia with principal executive offices in Melbourne, and reports in U.S. dollars while its functional currency is the Australian dollar.
Revenue drivers
- Prescription pharmaceutical sales — Total annual revenue rose from $57.9M in fiscal 2024 to $64.3M in fiscal 2026, but the provided filing excerpts do not break out product-level or segment-level revenue.
- Net income contribution — Net income was essentially flat across the period at $23.3M, $23.1M and $23.2M, implying stable margins alongside modest revenue growth.
- Cash generation — Operating cash flow fell from $27.3M in fiscal 2025 to $12.9M in fiscal 2026, diverging from stable reported net income.
Recent performance
Fiscal 2026 revenue was $64.3M, up from $61.1M in fiscal 2025 and $57.9M in fiscal 2024. Net income was $23.2M, effectively unchanged from $23.1M and $23.3M in the two prior years. Diluted EPS held at $0.46 in all three years. Operating cash flow dropped to $12.9M in fiscal 2026 from $27.3M a year earlier. At June 30, 2026 the company reported total assets of $204.0M, liabilities of $15.4M and shareholder equity of $188.6M.
Strategy
The filing references a Scheme process during which the ADS program is expected to remain in place, but the excerpts provided do not describe the strategic rationale or terms of that process. No specific product pipeline, capital allocation or research and development priorities are detailed in the supplied excerpts. Management commentary from Item 5 (Operating and Financial Review and Prospects) was not included in the source material provided.
Risks
- Cash flow divergence — Operating cash flow of $12.9M in fiscal 2026 was well below net income of $23.2M, a gap that would need explanation in the working capital and receivables detail that the excerpts do not provide.
- Flat earnings — Net income and diluted EPS have been unchanged for three consecutive years despite revenue growth, indicating costs or margins are absorbing the top-line increase.
- Corporate transaction overhang — The filing references a Scheme process involving Clinuvel's shares, creating uncertainty around the ADS listing and share structure until terms are disclosed.
- Dual-listing and currency exposure — The company reports in U.S. dollars while its functional currency is the Australian dollar, so results are exposed to AUD/USD translation, and the excerpts state no representation is made that translated amounts could actually be converted at those rates.
Outlook
The provided excerpts do not include management's forward guidance, revenue outlook or pipeline expectations. The only forward-looking statement in the source material concerns the ADS program remaining in place throughout the referenced Scheme process.